# Medicare Program; Announcement of the Re-Approval of the Joint Commission as an Accreditation Organization Under the Clinical Laboratory Improvement Amendments of 1988; Correction
**AGENCY:**
Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS).
**ACTION:**
Notice; correction.
**SUMMARY:**
This document corrects technical errors that appeared in the notice published in the May 24, 2024, *Federal Register* titled “Medicare Program; Announcement of the Reapproval of the Joint Commission as an Accreditation Organization Under the Clinical Laboratory Improvement Amendments of 1998”.
**DATES:**
*Effective date:* This correction notice is effective November 19, 2025.
*Applicability date:* The corrections in this notice are applicable to the re-approval of the Joint Commission as an Accreditation Organization Under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 from May 24, 2024 through May 24, 2030.
**FOR FURTHER INFORMATION CONTACT:**
Raymond Castillo, (312) 886-3595.
**SUPPLEMENTARY INFORMATION:**
**I. Background**
In FR Doc. 2024-11421 of May 24, 2024 (89 FR 45900 through 45901), there were technical errors that are identified and corrected in this correcting document.
**II. Summary of Errors**
On page 45900, in the *SUMMARY* section, we inadvertently omitted several entries from the list of specialties and subspecialties under the Clinical Laboratory Improvement Amendments (CLIA) of 1988. We also made inadvertent technical errors in several bulleted paragraphs.
**III. Correction of Errors**
In FR Doc. 2024-11421 of May 24, 2024 (89 FR 45900 through 45901), make the following correction:
1. On page 45900,
a. First column, sixth full paragraph ( *SUMMARY* section), lines 15 through 22, the phrase “Toxicology, and Endocrinology; Hematology, including routine hematology and coagulation; Immunohematology, including ABO Group, D (Rho) typing, Unexpected Antibody Detection, Compatibility Testing, and Antibody Identification; Pathology, including Histopathology, Oral Pathology, and Cytology.” is corrected to read, “Toxicology, Endocrinology, and Urinalysis; Hematology, including routine hematology and coagulation; Immunohematology, including ABO Group, D (Rho) typing, Unexpected Antibody Detection, Compatibility Testing, and Antibody Identification; Pathology, including Histopathology, Oral Pathology, Cytology, Histocompatibility, Radiobioassay, and Clinical Cytogenetics.”
b. Second column,
(1) Third bulleted paragraph, lines 2 and 3, the phrase “Toxicology, and Endocrinology.” is corrected to read, “Toxicology, Endocrinology, and Urinalysis.”.
(2) Sixth bulleted paragraph, lines 1 through 3, the paragraph “• Pathology, including Histopathology, and Oral Pathology, and Cytology.” is corrected to read as follows:
“• Histocompatibility.
• Radiobioassay.
• Clinical Cytogenetics.”
• Pathology, including Histopathology, and Oral Pathology, and Cytology.”
c. Third column,
(1) Third bulleted paragraph, lines 2 and 3, the phrase “Toxicology, and Endocrinology.” is corrected to read, “Toxicology, Endocrinology, and Urinalysis.”.
(2) Sixth bulleted paragraph, lines 1 through 3, the paragraph “• Pathology, including Histopathology, and Oral Pathology, and Cytology.” is corrected to read as follows:
“• Pathology, including Histopathology, and Oral Pathology, and Cytology.
• Histocompatibility.
• Radiobioassay.
• Clinical Cytogenetics.”
The Director of the Office of Strategic Operations and Regulatory Affairs of the Centers for Medicare & Medicaid Services (CMS), Kathleen Cantwell, having reviewed and approved this document, authorizes Trenesha Fultz-Mimms, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the *Federal Register* .
Trenesha Fultz-Mimms,
Federal Register Liaison, Centers for Medicare & Medicaid Services.